Join Saxo and get CHF 500 in commission credits
MedTech - Peer Group
This peer group analysis benchmarks a selected group of leading companies in the global medical technology sector. The peer group represents a broad cross-section of cardiovascular, diagnostics, imaging, orthopedics, and minimally invasive therapy markets.
MedTech Peer Group
Medtech Companies Ranked ranked by their AI & Autonomous Agent Revolution Potential (Next 5 Years)
Grok 4 Expert's take (May 6, 2026):
Rank | Company Name | Star Rating | Rationale |
|---|---|---|---|
1 | GE HealthCare Technologies Inc. (GEHC) | ★★★★★ (5/5) | Undisputed leader in agentic AI: 2025 prototypes demonstrate multi-agent systems for autonomous radiology workflows, pre/post-interpretive tasks, and virtual tumor boards—directly addressing radiologist shortages with device-integrated autonomy. |
2 | Siemens Healthineers AG (SHL) | ★★★★★ (5/5) | AI-Rad Companion automation plus Operational Twins with AI agents for real-time process optimization and scenario simulation; scales autonomous clinical + hospital operations better than most peers. |
3 | Koninklijke Philips N.V. (PHIA.AS) | ★★★★☆ (4.5/5) | Advancing agentic AI agents as "teammates" in acute care/imaging coordination, autonomous data synthesis, and MRI workflows—strong for reducing clinician cognitive load across care pathways. |
4 | Stryker Corporation (SYK) | ★★★★☆ (4.5/5) | Mako SmartRobotics with AI navigation on clear roadmap to greater sensor-driven autonomy in orthopedics and OR procedures. |
5 | Medtronic plc (MDT) | ★★★★☆ (4.5/5) | AiBLE ecosystem + Hugo RAS robotics deliver integrated AI-driven pre-op planning, real-time navigation, and post-op insights; strengthens procedural agent potential (slight upgrade vs. prior view). |
6 | Abbott Laboratories (ABT) | ★★★★ (4/5) | AI in FreeStyle Libre CGM, Ultreon imaging, and cardiac monitors for autonomous real-time alerts and chronic disease insights. |
7 | Boston Scientific Corporation (BSX) | ★★★☆ (3.5/5) | Solid AI in electrophysiology mapping and interventional devices; supportive data analytics but less agent-centric than imaging or robotics leaders. |
8 | Becton, Dickinson and Company (BDX) | ★★★☆ (3.5/5) | Incada/Pyxis AI for autonomous medication management and hospital logistics—strong backend ops play. |
9 | Olympus Corporation (7733.T) | ★★★ (3/5) | OLYSENSE/CADDIE AI for autonomous polyp detection in endoscopy; high-volume niche upside. |
10 | Edwards Lifesciences Corporation (EW) | ★★★ (3/5) | Acumen HPI provides strong predictive hypotension alerts/recommendations (proven outcome data); valuable but narrower than broad agentic platforms (modest bump vs. prior but still limited leverage). |
Medtech Companies Ranked ranked by their Defensiveness & Resilience in case of a Global Recession
Grok 4 Expert's take (May, 2026):
Rank | Ticker | Company Name | Star Rating | Rationale |
|---|---|---|---|---|
1 | BDX | Becton, Dickinson and Company (BDX) | ★★★★★ (5/5) | >90% recurring revenue from daily essential consumables (syringes, IV infusion, medication delivery, lab diagnostics) — completely inelastic demand and zero elective exposure; hospitals must buy regardless of budgets or credit crunch. |
2 | ABT | Abbott Laboratories (ABT) | ★★★★☆ (4.75/5) | High recurring CGM sensors (FreeStyle Libre), diagnostics reagents, plus nutrition (staple-like consumer demand) and chronic devices; diversified mix provides strong buffer vs pure procedure plays. |
3 | MDT | Medtronic plc (MDT) | ★★★★☆ (4.5/5) | Chronic cardiac implants, diabetes pumps/consumables, and monitoring deliver sticky recurring revenue in life-critical areas with limited deferral risk. |
4 | BSX | Boston Scientific Corporation (BSX) | ★★★★ (4/5) | Mostly urgent interventional cardiology and rhythm devices (essential procedures) with solid implant/consumable mix; lower capex reliance than imaging peers. |
5 | EW | Edwards Lifesciences Corporation (EW) | ★★★☆ (3.75/5) | Structural heart valves (TAVR) are life-saving but still procedure-based; some deferral possible in extreme austerity, though mortality risk limits cuts vs pure elective. |
6 | 7733.T | Olympus Corporation (7733.T) | ★★★ (3/5) | Endoscopy mix of capital scopes + disposables; many GI procedures are semi-elective and can be delayed in deep recession. |
7 | PHIA.AS | Koninklijke Philips N.V. (PHIA.AS) | ★★☆ (2.75/5) | Patient monitoring has some recurring element but heavy imaging/connected-care capex exposure makes it vulnerable to hospital budget freezes. |
8 | SHL | Siemens Healthineers AG (SHL) | ★★☆ (2.5/5) | Strong diagnostics recurring but dominant imaging equipment sales are highly cyclical; hospitals defer big-ticket orders first in downturns. |
9 | GEHC | GE HealthCare Technologies Inc. (GEHC) | ★★ (2/5) | Highest capex sensitivity among imaging leaders (MRI/CT/ultrasound systems); service revenue helps but new equipment sales collapse in credit-crunched recessions. |
10 | SYK | Stryker Corporation (SYK) | ★★ (2/5) | Significant elective orthopedic joint replacements and capital robotics exposure; highest deferral risk in severe unemployment/budget cuts. |